Suchergebnisse
Suchergebnisse:
Vor 20 Stunden · NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb Co. (BMY) announced Monday that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo (nivolumab) plus...
- (2)
Vor 20 Stunden · NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb Co. (BMY) announced Monday that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo (nivolumab) plus...